We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
FMS Launches kinexus Digital Platform for Home Dialysis Care
Read MoreHide Full Article
Key Takeaways
FMS launched kinexus globally, a digital platform to support home dialysis programs and connected care.
kinexus unifies remote monitoring, prescriptions and workflows for peritoneal and home hemodialysis.
Built on Huma Cloud, kinexus adds modular upgrades and integrated supply ordering for PD and HHD.
Fresenius Medical Care AG & Co. (FMS - Free Report) recently announced the global launch of kinexus, a digital platform to support home dialysis programs and enhance connected, patient-focused care. The platform integrates remote therapy monitoring, prescription management and operational workflows for both peritoneal dialysis (PD) and home hemodialysis (HHD) within a single system.
Per management, the launch of kinexus marks a milestone in strengthening home dialysis programs through digital infrastructure and demonstrates FMS’ long-term commitment to home therapies globally. By launching a unified platform that connects therapy management and operational workflows, the company is building a digital foundation designed for the realities of home dialysis care.
Likely Trend of FMS Stock Following the News
Shares of FMS have gained 4.9% since the announcement on Wednesday. In the year-to-date (YTD) period, shares of the company have lost 7.9% compared with the industry’s 16.7% decline. However, the S&P 500 has risen 10.2% in the same timeframe.
Fresenius Medical Care is likely to benefit from the launch of kinexus as healthcare providers are adopting digital solutions to improve patient outcomes and operational efficiency. By consolidating therapy management, remote monitoring and supply ordering into a single platform, kinexus may help healthcare teams streamline workflows and deliver more personalized care. The launch also supports Fresenius Medical Care’s growth in the home dialysis market.
FMS currently has a market capitalization of $11.29 billion.
Image Source: Zacks Investment Research
More on the kinexus Platform
Built on the Huma Cloud Platform, kinexus features a modular design that supports current and future home dialysis functions within a consistent regulatory framework. Its flexible architecture allows FMS to add new capabilities over time while maintaining a unified digital ecosystem for home therapies.
In addition, the kinexus platform includes integrated supply ordering capabilities for both PD and HHD therapies. This feature simplifies workflows for healthcare professionals and creates a seamless treatment experience for patients.
Industry Prospects Favoring the Market
Going by the data provided by Market Research Intellect, the home dialysis systems market is valued at $6 billion in 2026 and is expected to witness a CAGR of 8.5% through 2033.
The market is expanding, driven by the growing rates of End-Stage Renal Disease and Chronic Kidney Disease, artificial intelligence and Internet of Things integration, growth in wearable and portable dialysis solutions and growth of telehealth and virtual training services. Government initiatives and supportive reimbursement policies are also driving market growth.
Other News
In May, Fresenius Medical Care reported first-quarter 2026 results, with its earnings and revenues missing their respective consensus estimate. However, the company’s bottom-line growth continued to be driven by strong efficiency gains from its FME25+ transformation program.
Margin expansion and stronger free cash flow reflected cost savings. While U.S. treatment volumes and China operations faced headwinds, management remains optimistic about growth drivers such as the rollout of the 5008X CAREsystem and HighVolumeHDF therapy, AI-enabled tools and clinic optimization initiatives. The company maintained its full-year outlook despite TDAPA reimbursement changes, inflation and regulatory challenges.
Fresenius Medical Care currently carries a Zacks Rank #5 (Strong Sell).
Some better-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , Globus Medical (GMED - Free Report) and Intuitive Surgical (ISRG - Free Report) .
West Pharmaceutical, sporting a Zacks Rank #1 (Strong Buy) at present, reported first-quarter 2026 earnings per share (EPS) of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.
West Pharmaceutical has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.
Globus Medical, currently sporting a Zacks Rank #1, reported first-quarter 2026 adjusted EPS of $1.12, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%.
Globus Medical has an estimated long-term earnings growth rate of 10.2%. GMED’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.
Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.
Intuitive Surgical has a long-term estimated growth rate of 14.6%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
FMS Launches kinexus Digital Platform for Home Dialysis Care
Key Takeaways
Fresenius Medical Care AG & Co. (FMS - Free Report) recently announced the global launch of kinexus, a digital platform to support home dialysis programs and enhance connected, patient-focused care. The platform integrates remote therapy monitoring, prescription management and operational workflows for both peritoneal dialysis (PD) and home hemodialysis (HHD) within a single system.
Per management, the launch of kinexus marks a milestone in strengthening home dialysis programs through digital infrastructure and demonstrates FMS’ long-term commitment to home therapies globally. By launching a unified platform that connects therapy management and operational workflows, the company is building a digital foundation designed for the realities of home dialysis care.
Likely Trend of FMS Stock Following the News
Shares of FMS have gained 4.9% since the announcement on Wednesday. In the year-to-date (YTD) period, shares of the company have lost 7.9% compared with the industry’s 16.7% decline. However, the S&P 500 has risen 10.2% in the same timeframe.
Fresenius Medical Care is likely to benefit from the launch of kinexus as healthcare providers are adopting digital solutions to improve patient outcomes and operational efficiency. By consolidating therapy management, remote monitoring and supply ordering into a single platform, kinexus may help healthcare teams streamline workflows and deliver more personalized care. The launch also supports Fresenius Medical Care’s growth in the home dialysis market.
FMS currently has a market capitalization of $11.29 billion.
Image Source: Zacks Investment Research
More on the kinexus Platform
Built on the Huma Cloud Platform, kinexus features a modular design that supports current and future home dialysis functions within a consistent regulatory framework. Its flexible architecture allows FMS to add new capabilities over time while maintaining a unified digital ecosystem for home therapies.
In addition, the kinexus platform includes integrated supply ordering capabilities for both PD and HHD therapies. This feature simplifies workflows for healthcare professionals and creates a seamless treatment experience for patients.
Industry Prospects Favoring the Market
Going by the data provided by Market Research Intellect, the home dialysis systems market is valued at $6 billion in 2026 and is expected to witness a CAGR of 8.5% through 2033.
The market is expanding, driven by the growing rates of End-Stage Renal Disease and Chronic Kidney Disease, artificial intelligence and Internet of Things integration, growth in wearable and portable dialysis solutions and growth of telehealth and virtual training services. Government initiatives and supportive reimbursement policies are also driving market growth.
Other News
In May, Fresenius Medical Care reported first-quarter 2026 results, with its earnings and revenues missing their respective consensus estimate. However, the company’s bottom-line growth continued to be driven by strong efficiency gains from its FME25+ transformation program.
Margin expansion and stronger free cash flow reflected cost savings. While U.S. treatment volumes and China operations faced headwinds, management remains optimistic about growth drivers such as the rollout of the 5008X CAREsystem and HighVolumeHDF therapy, AI-enabled tools and clinic optimization initiatives. The company maintained its full-year outlook despite TDAPA reimbursement changes, inflation and regulatory challenges.
Fresenius Medical Care AG & Co. KGaA Price
Fresenius Medical Care AG & Co. KGaA price | Fresenius Medical Care AG & Co. KGaA Quote
FMS’ Zacks Rank & Key Picks
Fresenius Medical Care currently carries a Zacks Rank #5 (Strong Sell).
Some better-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , Globus Medical (GMED - Free Report) and Intuitive Surgical (ISRG - Free Report) .
West Pharmaceutical, sporting a Zacks Rank #1 (Strong Buy) at present, reported first-quarter 2026 earnings per share (EPS) of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.
West Pharmaceutical has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.
Globus Medical, currently sporting a Zacks Rank #1, reported first-quarter 2026 adjusted EPS of $1.12, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%.
Globus Medical has an estimated long-term earnings growth rate of 10.2%. GMED’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.
Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.
Intuitive Surgical has a long-term estimated growth rate of 14.6%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.